logo

Y-Mabs Therapeutics, Inc. (YMAB)



Trade YMAB now with
  Date
  Headline
5/31/2022 11:26:25 AM Wedbush Reiterates Y-mAbs Therapeutics, Inc. (YMAB) At Outperform With $21 Price Target
5/10/2022 4:57:16 PM Wedbush Is Raising Y-mAbs Therapeutics, Inc. (YMAB) FY22 Rev. Estimate To 61.0 M From 48.0 M
5/10/2022 4:56:54 PM Wedbush Is Lowering Y-mAbs Therapeutics, Inc. (YMAB) FY22 Estimate To -2.26 From -1.43
5/10/2022 4:56:35 PM Wedbush Is Cutting Y-mAbs Therapeutics, Inc. (YMAB) Q4 22 Estimate To -0.28 From 0.44
5/10/2022 4:56:15 PM Wedbush Is Cutting Y-mAbs Therapeutics, Inc. (YMAB) Q3 22 Estimate To -0.69 From -0.46
5/10/2022 4:56:01 PM Wedbush Is Increasing Y-mAbs Therapeutics, Inc. (YMAB) Q2 22 Estimate To -0.65 From -0.69
5/10/2022 4:55:42 PM Wedbush Reiterates Y-mAbs Therapeutics, Inc. (YMAB) At Outperform With $21 Down From $28 Price Target
9/13/2021 9:13:00 AM Y-mAbs Announces Priority Review Of BLA For DANYELZA In China
2/17/2021 8:13:13 PM Y-mAbs Therapeutics Prices Public Offering Of 2.44 Mln Shares At $41.00/shr